Tes gene methylation in different malignancy gliomas

Abstract

The TES gene methylation is one of several potential epigenetic prognostic markers in glioblastoma. TES gene expression is involved in cell adhesion, cell spreading and in the reorganization of the actin cytoskeleton. Also, plays a role in the regulation of cell proliferation, acts as a tumor suppressor - inhibits tumor cell growth. Methods: Were investigated 95 patients with different grade gliomas: grade I - 11 samples, grade II - 25, grade III - 16 and grade IV (Glioblastoma) - 43 samples. Tumor DNA was extracted from 25- 40mg of frozen tissue and the methylation status of TES gene promoter was determined by bisulfite treatment of DNA. TES gene methylation was performed by using methylation specific polymerase chain reaction (MS-PCR) method. MS- PCR products were separated by electrophoresis on 2% agarose gels with ethidium bromide and visualized under UV illumination. Results: 61.05% of all patients had TES gene methylation. In different malignancy grade gliomas TES gene promoter methylation frequencies were varied. Glioblastomas demonstrated TES promoter methylation in 79.07% (34/43). Grade I (0/11) gliomas have not showed TES promoter methylation. TES promoter methylation was observed in 56% (14/25) of grade II gliomas and 62.5% (10/16) of grade III gliomas. In conclusion: TES gene methylation is related with glioma malignancy. TES gene methylation may be involved in gliomagenis process and might be one of the potential epigenetic prognostic markers in glioblastoma. Acknowledgement: This research was funded by a grant (No. LIG-11/2012) from the Research Council of Lithuania.